PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
17.00
-0.75 (-4.22%)
Oct 30, 2025, 4:00 PM EDT - Market closed
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
$114,125
Profits / Employee
$904,964
Market Cap
425.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56 | -34 | -37.78% |
| Dec 31, 2023 | 90 | -21 | -18.92% |
| Dec 31, 2022 | 111 | 16 | 16.84% |
| Dec 31, 2021 | 95 | -155 | -62.00% |
| Dec 31, 2020 | 250 | -50 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRTC News
- 8 days ago - PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group - Business Wire
- 4 weeks ago - PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF - Business Wire
- 2 months ago - PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - PureTech Health plc – Half-Year Report - Business Wire
- 2 months ago - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF - Business Wire
- 2 months ago - PureTech Health: Notice of Half-Yearly Results - Business Wire
- 2 months ago - PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint - Business Wire
- 2 months ago - PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases - Business Wire